Literature DB >> 10232602

Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.

S Fujii1, K Fujimoto, K Shimizu, T Ezaki, F Kawano, K Takatsuki, M Kawakita, K Matsuno.   

Abstract

The use of antigen-presenting dendritic cells (DCs) is currently proposed for tumor immunotherapy through generation of CTLs to tumor antigens in cancer patients. In this study, DCs were differentiated using granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha from CD34+ hematopoietic progenitor cells that had been mobilized into the peripheral blood. To use the phagocytic activity of DCs for processing and presentation of tumor antigens, we established DC clusters containing immature DCs by preserving proliferating cell clusters without mechanical disruption. After an 11-day culture, the developed clusters contained not only typical mature DCs but also immature DCs that showed active phagocytosis of latex particles, suggesting that the clusters consisted of DCs of different maturational stages. These heterogeneous clusters could present an exogenous protein antigen, keyhold limpet hemocyanin, to both CD4+ and CD8+ T lymphocytes. Furthermore, in three acute myelogeneous leukemia patients, clusters pulsed with autologous irradiated leukemic cells could also induce antileukemic CTLs. The mechanical disruption of clusters abrogated the induction of CTLs to leukemic cells as well as to hemocyanin. This observation gives an important information for the use of heterogeneous DC clusters derived from autologous peripheral blood CD34+ cells in the case of immunotherapy for leukemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Antitumor activities of human dendritic cells derived from peripheral and cord blood.

Authors:  Jin-Kun Zhang; Jun Li; Hai-Bin Chen; Jin-Lun Sun; Yao-Juan Qu; Juan-Juan Lu
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 2.  The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.

Authors:  Changjin Yuan; Guanhua Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 3.  Immunological weapons against acute myeloid leukaemia.

Authors:  Joanna Galea-Lauri
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

4.  Phagocytosis of co-developing neutrophil progenitors by dendritic cells in a culture of human CD34(+) cells with granulocyte colony-stimulating factor and tumor necrosis factor-alpha.

Authors:  Yoshinobu Saito; Yong Mei Guo; Makoto Hirokawa; Kunie Saito; Atsushi Komatsuda; Naoto Takahashi; Masumi Fujishima; Naohito Fujishima; Junsuke Yamashita; Kenichi Sawada
Journal:  Int J Hematol       Date:  2008-05-20       Impact factor: 2.490

5.  Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells.

Authors:  Björn Schöttker; Ingo G H Schmidt-Wolf
Journal:  Ger Med Sci       Date:  2011-08-04

6.  Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease.

Authors:  H Yoneyama; K Matsuno; Y Zhang; M Murai; M Itakura; S Ishikawa; G Hasegawa; M Naito; H Asakura; K Matsushima
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

7.  Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.

Authors:  S Fujii; K Shimizu; K Fujimoto; T Kiyokawa; T Shimomura; M Kinoshita; F Kawano
Journal:  Jpn J Cancer Res       Date:  1999-10

8.  PD-L1 Expression Affects Neoantigen Presentation.

Authors:  Masahiro Okada; Kanako Shimizu; Tomonori Iyoda; Shogo Ueda; Jun Shinga; Yoshiki Mochizuki; Takashi Watanabe; Osamu Ohara; Shin-Ichiro Fujii
Journal:  iScience       Date:  2020-06-04

Review 9.  Commercial nanoparticles for stem cell labeling and tracking.

Authors:  Yaqi Wang; Chenjie Xu; Hooisweng Ow
Journal:  Theranostics       Date:  2013-07-20       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.